Eton Pharmaceuticals, Inc. (ETON)

Market Cap	374.88M
Revenue (ttm)	34.68M
Net Income (ttm)	-5.48M
Shares Out	25.84M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	53.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	230,410
Open	14.56
Previous Close	14.39
Day's Range	14.30 - 14.91
52-Week Range	3.03 - 18.41
Beta	1.41
Analysts	Strong Buy
Price Target	24.00 (+65.4%)
Earnings Date	Mar 13, 2025

About ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortison...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 13, 2018
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: ETON
• Website: https://www.etonpharma.com

Financial Performance

In 2023, Eton Pharmaceuticals's revenue was $31.64 million, an increase of 48.90% compared to the previous year's $21.25 million. Losses were -$936,000, -89.62% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for ETON stock is "Strong Buy." The 12-month stock price forecast is $24.0, which is an increase of 65.40% from the latest price.

Price Target

$24.0

(65.40% upside)

Analyst Consensus: Strong Buy